MedDataX Logo

Prospective Study of a New Endolumenal Device Used During Endoscopic Polypectomy in the Colon

NCT ID: NCT04657601

Last Updated: 2020-12-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-15

Study Completion Date

2022-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective observational study will evaluate the performance of the DiLumen C2 Endolumenal Interventional Platform and its instruments. Up to 100 subjects will be enrolled at up to 5 clinical sites. Patient data will be collected before the procedure, during the procedure, and up until the patient is discharged from the hospital.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a prospective, post-market evaluation of the performance of the DiLumen C2 Endolumenal Interventional Platform ("C2 device") used as an endoscopic dual balloon accessory device used to ensure complete positioning, visualization, and diagnosis in endoscopic treatments in the large intestine. The DiLumen Endolumenal Interventional Knife ("IK device") and the DiLumen Endolumenal Interventional Grasper ("IG device") are disposable instruments used with the C2 device. These devices are cleared by the US Food and Drug Administration (FDA) for commercial use in endolumenal therapies and will be used on-label in this study. The overall goal of this study is to evaluate the clinical performance of the C2 device and its related instruments. Intra-procedure parameters (procedure timepoints, anesthesia use, polyp location and description), final pathology/histology, and general complications will also be evaluated. Investigators will also be asked to assess the ease of use of the C2Interventional Platform.

To accomplish this goal, up to 100 subjects will be enrolled at up to 5 clinical sites and treated using the C2 device and related instruments. Evaluations will be performed pre-procedure, during the procedure, and at discharge. Assessments will include polyp classification/pathology, procedure timepoints, final pathology/histology, adverse events, and ease of use. As per the FDA cleared product labeling this study will be limited to subjects undergoing an endoscopic procedure to remove polyps in the large intestine.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Polyps of Colon

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Intestinal Polyps Pathologic Condition, Anatomical Polyps

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Group

Patients undergo polypectomy facilitated by the study device.

DiLumen C2 Endolumenal Interventional Platform

Intervention Type DEVICE

Dual balloon accessory to an endoscope and related instruments

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DiLumen C2 Endolumenal Interventional Platform

Dual balloon accessory to an endoscope and related instruments

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Men or women 18-85 years of age.
2. Have the ability to understand the requirements of the study, to provide written informed consent, and to comply with the study protocol.
3. Scheduled for endoscopic removal of suspected colorectal adenomatous polyps which are sessile or polypoid lesions.
4. Have, in the opinion of the Investigator(s) or co-investigator(s), no medical contraindication to endoscopic submucosal dissection (ESD).

Exclusion Criteria

1. Have a contraindication to colonoscopy, including but not limited to active colitis, diverticulitis, perforation, or stricture.
2. Have a history of open or laparoscopic colorectal surgery.
3. Have a history of Inflammatory Bowel Disease (IBD).
4. Have a suspected invasive malignancy on polyp assessment.
5. Any medical or surgical condition that would preclude the potential benefit ESD.
6. Any case where the device or instrument would be too large or too small to achieve a successful result.
7. Anatomy or other factors that prohibit safe access to the large intestine such as previous radiation therapy to the affected area.
8. History of AIDS, HIV, or active hepatitis.
9. History of mental illness, including psychological or neurological conditions (addiction to substances such as alcohol. e.g.) that in the investigator's opinion would pre-empt their ability or willingness to participate in the study.
10. Has cardiopulmonary conditions that present prohibitive anesthesia risk.
11. Has uncorrectable coagulopathy or hemorrhagic diathesis.
12. Has an active infection or fever.
13. Has allergy to any component of the treatment procedure.
14. Patients who are pregnant.
15. Pediatric case (Age \< 18 years)
16. Any case in which use of the DiLumen C2 device is not needed.
17. Any case not described in the indications.
18. Currently involved in another investigational product for similar purposes.
19. Prisoners.
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Lumendi, LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

USLUM 1802 or 2020-01

Identifier Type: -

Identifier Source: org_study_id